Needham & Company LLC restated their buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $4.25 price objective on the stock.
Separately, StockNews.com initiated coverage on shares of OncoCyte in a research note on Tuesday. They set a sell rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, OncoCyte currently has a consensus rating of Hold and a consensus price target of $4.06.
Get Our Latest Research Report on OCX
OncoCyte Price Performance
OncoCyte (NASDAQ:OCX – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The business had revenue of $0.10 million for the quarter.
Insider Transactions at OncoCyte
In other news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were purchased at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now directly owns 6,244,405 shares of the company’s stock, valued at approximately $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrea S. James acquired 33,670 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief financial officer now directly owns 33,670 shares of the company’s stock, valued at $99,999.90. The disclosure for this purchase can be found here. Insiders own 1.94% of the company’s stock.
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Recommended Stories
- Five stocks we like better than OncoCyte
- The How And Why of Investing in Oil Stocks
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What Are Dividend Champions? How to Invest in the Champions
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How to Invest in the FAANG Stocks
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.